These immediate efforts resemble what happened with severe acute respiratory syndrome (SARS) in 2002-2003. Both of them belong to the same group of coronavirus, which are enveloped RNA viruses, distributed broadly, and able to cause respiratory disorders. As a well-recognized expert in the antibody market, Creative Biolabs has built neutralizing antibody (nAb) platforms and provides end-to-end antibody development solutions to help global populations to fight against SARS-CoV-2, according to the research from SARS coronavirus (SARS-CoV).